Retinitis Pigmentosa: Genes and Disease Mechanisms

Stefano Ferrari*,1, Enzo Di Iorio1, Vanessa Barbaro1, Diego Ponzin1, Francesco S. Sorrentino2 and Francesco Parmeggiani2

1The Veneto Eye Bank Foundation, Mestre-Venice, Italy
2Department of Ophthalmology, University of Ferrara, Ferrara, Italy

Abstract: Retinitis pigmentosa (RP) is a group of inherited disorders affecting 1 in 3000-7000 people and characterized by abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium of the retina which lead to progressive visual loss. RP can be inherited in an autosomal dominant, autosomal recessive or X-linked manner. While usually limited to the eye, RP may also occur as part of a syndrome as in the Usher syndrome and Bardet-Biedl syndrome. Over 40 genes have been associated with RP so far, with the majority of them expressed in either the photoreceptors or the retinal pigment epithelium. The tremendous heterogeneity of the disease makes the genetics of RP complicated, thus rendering genotype-phenotype correlations not fully applicable yet. In addition to the multiplicity of mutations, in fact, different mutations in the same gene may cause different diseases. We will here review which genes are involved in the genesis of RP and how mutations can lead to retinal degeneration. In the future, a more thorough analysis of genetic and clinical data together with a better understanding of the genotype-phenotype correlation might allow to reveal important information with respect to the likelihood of disease development and choices of therapy.

Received on: February 14, 2011 - Revised on: March 28, 2011 - Accepted on: April 11, 2011

Keywords: Syndromic retinitis pigmentosa, non-syndromic retinitis pigmentosa, retina, dominant, recessive, X-linked, mutations.

1. WHAT IS RETINITIS PIGMENTOSA?

Retinitis pigmentosa (RP) is a class of diseases involving progressive degeneration of the retina, typically starting in the mid-periphery and advancing toward the macula and fovea. Typical symptoms include night blindness followed by decreasing visual fields, leading to tunnel vision and eventually legal blindness or, in many cases, complete blindness [1]. On the cellular level, this correlates with a predominantly affected rod photoreceptor system. In later stages, the disease may further affect the cone photoreceptor eventually causing complete blindness. The diseased photoreceptors undergo apoptosis [2], which is reflected in reduced outer nuclear layer thickness within the retina, as well as in lesions and/or retinal pigment deposits in the fundus. Patients may lose a significant portion of their photoreceptors before experiencing loss of visual acuity. Clinical hallmarks are (i) an abnormal fundus with bone-spicule deposits and attenuated retinal vessels, (ii) abnormal, diminished or absent a- and b-waves in the electroretinogram (ERG) and (iii) reduced visual field. Symptoms typically start in the early teenage years and severe visual impairment occurs by ages 40 to 50 years (reviewed in [3]). A multicenter study evaluating visual acuity (VA) data from 999 patients (age 45 years or older) with different genetic subtypes of RP found that 52% had a VA of 20/40 or better, 69% of 20/70 or better, 25% of 20/200 or worse and 0.5% had no light perception in both eyes [4]. There are also early-onset forms of RP (the earliest is indistinguishable from Leber congenital amaurosis) and other late-onset or even non-penetrant forms.

RP, broadly defined to include simple, syndromic and systemic disease, has a worldwide prevalence of 1:3000 to 1:7000 people. Usually, no sex predilection exists. However, as X-linked RP is expressed only in males, statistically men may be affected slightly more than women. RP shows no ethnic specificity, but RP caused by mutations in particular genes may be more frequent in certain isolated or consanguineous populations (such as the USH3 gene associated with type III Usher syndrome, normally rare, but more common among Finns and Ashkenazi Jews).

The genetics of RP is varied. After the first report describing a linkage of an RP locus to a DNA marker on human chromosome X in 1984 [5], over 40 genes have been associated with RP (Table 1). Non-syndromic or “simple” cases may be inherited as an autosomal dominant (20-25%); Fig. (1)), autosomal recessive (15-20%; Fig. (2)), X-linked recessive (10-15%; Fig. (3)), or sporadic/simplex traits (30%), and 5% may be early-onset and grouped as part of Leber congenital amaurosis (LCA). Rarer forms also exist, such as X-linked dominant, mitochondrial, and digenic (due to mutations in two different genes). While RP is a disease usually limited to the eye, there are syndromic forms involving multiple organs and pleiotropic effects as well as systemic forms wherein the retinal disease is secondary to a system-wide pathology. The most frequent forms of syndromic RP are Usher syndrome (RP usually develops by the early teenage years) and Bardet-Biedl syndrome.
Table 1. Summary of Genes Associated with RP (Adapted from http://www.sph.uth.tmc.edu/retnet/)

| Disease                                      | Total No. of Genes and Loci | No. of Identified Genes |
|----------------------------------------------|------------------------------|-------------------------|
| Leber congenital amaurosis, autosomal dominant| 1                            | 1                       |
| Leber congenital amaurosis, autosomal recessive| 9                            | 8                       |
| Retinitis pigmentosa, autosomal dominant      | 17                           | 17                      |
| Retinitis pigmentosa, autosomal recessive     | 24                           | 21                      |
| Retinitis pigmentosa, X-linked                | 6                            | 2                       |
| Usher syndrome, autosomal recessive           | 11                           | 9                       |
| Bardet-Biedl syndrome, autosomal recessive    | 12                           | 12                      |

Fig. (1). Pattern of autosomal dominant RP inheritance.

Approximately 20-30% of patients with RP have an associated non-ocular disease and would be classified as having syndromic RP. A list of non-syndromic and syndromic RP is maintained through RetNet (http://www.sph.uth.tmc.edu/retnet/). Table 2 shows the overall prevalence of non-syndromic or “simple” RP (not affecting other organs or tissues) and the proportion of the most common syndromic (affecting other systems such as hearing) or systemic (affecting multiple organs) RP.

The genetics of RP is complicated and clear genotype-phenotype correlations are not yet possible. In addition to the multiplicity of mutations, in fact, (i) different mutations in the same gene may cause different diseases and (ii) the same mutation can exhibit intra- and inter-familial phenotypic variability (as for BEST1 mutations). For example, the vast majority of RHO mutations show a classical autosomal dominant inheritance leading to RP. Nevertheless, a few mutations show an autosomal recessive inheritance or lead to night blindness only [6]. Similarly, RPGR, the major X-linked recessive RP gene, is associated with mutations in male patients and no male-to-male transmission of the phenotype has ever been observed. However, families with
Fig. (2). Pattern of autosomal recessive RP inheritance.

- A: Normal allele
- a: mutated allele
- Two germline mutations aa (one from each parent to develop disease)
- Equally transmitted by men and women
- Two unaffected people who each carry one copy of the mutated gene (Aa) have a 25% chance with each pregnancy of having a child affected

Fig. (3). Pattern of X-linked RP inheritance.

- X: Normal allele
- X: mutated allele
- Mutant genes are on the X (sex) chromosome
- All men who inherit the mutation are affected (only one X chromosome)
- Affected males pass the defective X chromosome to all of their daughters, who are described as obligate carriers (XX), but not affected
- Female carriers pass the defective X chromosome to half their sons (who are affected by the disease) and half their daughters (who are therefore also carriers)
dominant inheritance pattern and female carriers showing disease symptoms of variable degree (likely due to the dominant nature of some of the mutations or non-random X-inactivation in the affected tissue) have also been described [6]. Furthermore, mutations in some genes are associated with incomplete penetrance, thus making genotype-phenotype correlations even more difficult.

In the next paragraphs we will overview the genes involved in the genesis of RP and how mutations can lead to patho-physiological consequences. A homogeneous and unique pattern of disease development cannot be envisaged as genes affected in RP are multiple and cover different steps of the visual cycle (phototransduction, retinal metabolism, tissue development and maintenance, cellular structure, splicing). For each of the main genes involved in RP, we will therefore evaluate the frequency of the mutations associated and how these lead to retinal degeneration and eventually RP.

2. THE VISUAL CYCLE

In order to understand better how mutations in the genes involved in RP affect the activity of the proteins, a brief outline of the molecular bases of vision needs to be described.

Human vision begins when light enters the eye and is focused by the lens onto the photosensitive tissue at the back of the eye, the retina (Fig. (4)). Light-sensitive cells in the retina - the rod and cone photoreceptors – capture the incoming photons. The photoreceptors are polarized cells that consist of a synaptic region, a cell body, an inner segment (IS) and an outer segment (OS). The “molecular machinery” involved in biosynthesis, energy metabolism and membrane trafficking reside within the IS, which is connected to the OS via the so called connecting cilium. The OS is comprised of membranous discs surrounded by a plasma membrane. Over 90% of the total protein in the OS is rhodopsin, which resides both within the membrane of the discs and in the surrounding plasma membrane. Rhodopsin is one of the most extensively studied G-protein coupled receptors and its ligand-binding domain is buried within the transmembrane portion of the molecule. It is highly conserved among vertebrates and rhodopsin-like proteins can also be found in lower vertebrates. Vision in vertebrates begins with the absorption of light by the rod photoreceptor “visual pigment”, rhodopsin, which consists of an apoprotein, opsin (a single 384 amino acid polypeptide chain), and a chromophore (11-cis retinaldehyde, derived from vitamin A) attached to the opsin by a Schiff base bond. The absorption of light by rhodopsin causes isomerization of 11-cis retinal to all-trans retinal, which changes opsin conformation, thus initiating vision. All-trans retinal is liberated from opsin in the photoreceptor cells and is reduced to all-trans retinol, which moves to the retinal pigment epithelium (RPE). For vision to continue, 11-cis retinal has to be produced again from all-trans retinol in the RPE. This process is carried out by a 65kDa isomerohydrolase expressed in the RPE called RPE65 [7, 8]. The light-activated rhodopsin interacts with and activates its cognate G (GTP-binding) protein, transducin, which subsequently initiates a canonical second-messenger signaling pathway via the heterotetrameric phosphodiesterase (PDE) 6 complex.

3. NON-SYNDROMIC RETINITIS PIGMENTOSA

3.1. Autosomal Dominant RP

To date mutations in 22 different genes are associated with autosomal dominant RP (adRP) (http://www.sph.uth.tmc.edu/retnet/; Fig. (1) and Table 3). However, only a few of these account for a relevant percentage of cases and include RHO (26.5%), PRPH2/RDS (5-9.5%), PRPF31 (8%) and RP1 (3.5%).

Rhodopsin

As above described, rhodopsin (RHO) is the first component of the visual transduction pathway and is activated by absorption of light in the rod photoreceptor cells of the retina (reviewed in [10]). Mutations in the RHO gene account for 30 to 40% of all adRP, with more than 100 different mutations (but Pro23His is found in approximately 10% of Americans affected with adRP). The analysis of mutant rhodopsins suggests that mutations can impair protein folding, 11-cis retinal chromophore binding, G-protein coupling/activation, and/or cellular trafficking of the rhodopsin protein. In addition, mutations in RHO can also lead to autosomal dominant congenital night blindness (CNB) and autosomal recessive retinitis pigmentosa (arRP).
Fig. (4). Haematoxylin-stained section of the human retina (scale bar = 100μm).

Table 3. Genes, Proteins and their Functions in Autosomal Dominant RP (Adapted from [6, 9] and http://www.sph.uth.tmc.edu/retnet/)

| Gene               | Protein                                      | % of all cases | Function                                   | Other diseases/phenotypes                  |
|--------------------|----------------------------------------------|----------------|--------------------------------------------|--------------------------------------------|
| BEST1              | Bestrophin-1                                 |                | Anion channel                              | Recessive RP                               |
| CA4                | Carbonic anhydrase IV                        | Arg14Trp found in 4% of Swedish controls | Zn-containing enzyme that catalyzes hydration of carbon dioxide | None                                       |
| CRX                | Cone-rod homeobox protein                    | 1.0            | Transcription factor                       | Recessive and dominant LCA, dominant CORD  |
| FSCN2              | Fascin homolog 2, actin-bundling protein     |                | Cellular structure                         | None                                       |
| GUCA1B             | Guanylate cyclase activator 1B               |                | Phototransduction                          | Dominant MD                                |
| IMPDH1             | Inosine 5’-monophosphate dehydrogenase 1     | 2.5            | Regulation of cell growth                  | Dominant LCA                               |
| KLHL7              | Kelch-like 7                                 |                | Ubiquitin-proteasome protein degradation   | None                                       |
| NR2E3              | Nuclear receptor subfamily 2, group E, member 3 |                | Transcription factor                       | Recessive RP; Recessive enhanced S-cone syndrome |
| NRL                | Neural retina leucine zipper protein          |                | Tissue development and maintenance        | Autosomal recessive RP                     |
| PRPF3              | PRP3 pre-mRNA processing factor 3 homolog (S cerevisiae) | 1.0 | Splicing                                  | None                                       |
| PRPF8              | PRP8 pre-mRNA processing factor 8 homolog (S cerevisiae) | 3.0 | Splicing                                  | None                                       |
| PRPF31             | PRP31 pre-mRNA processing factor 31 homolog (S cerevisiae) | 8.0 | Splicing                                  | None                                       |
| PRPH2 (RDS)        | Peripherin 2                                 | 5-9.5          | Photoreceptor outer segment structure      | Digenic forms with ROM1                    |
| RDH12              | Retinol dehydrogenase 12                     |                | Phototransduction                          | Recessive LCA                              |
A documented case of arRP resulted from a mutation in the RHO gene that led to a protein that was missing the 6th and 7th transmembrane domains, including the 11-cis retinal binding site [11]. Differently, RHO mutants associated with CNB appear to arise as a result of a constitutively active form of opsin that can catalytically activate the G-protein transducin in the absence of chromophore and in absence of light. Despite the amount of knowledge in adRP caused by mutations in RHO, therapeutic approaches have not proceeded at the same pace. Recently, visual function in P23H transgenic rats was restored following subretinal delivery of recombinant AAV vectors expressing the Bip/Grp78 gene (a chaperone protein able to promote trafficking of misfolded Pro23His rhodopsin to the cell membrane) [12]. Improved retinal function was also obtained in a mouse model of dominant RP following subretinal administration of recombinant AAV vectors carrying RNAi-based suppressors [13].

Pre-mRNA Processing Factor 31 (PRPF31)

PRPF31 was recently suggested to play a major role in adRP, with mutations ranging from 1 to 8% in adRP cohorts from various geographical origins (6.7% in a French adRP cohort) and higher frequencies in the United States [14]. PRPF31 is a pre-mRNA splicing factor of 61kDa, which is integral to the U4/U6+U5 trimer. To date over 40 mutations have been located in different parts of the gene and comprise missense substitutions, splice-site mutations, deletions and insertion. Interestingly, PRPF31 is one of three pre-mRNA splicing factors identified as causing adRP. Two other pre-mRNA splicing factors have also been implicated in adRP: PRPF3 (RP18) found in 1% of cases and PRPF8 (RP13) found in 3% of cases (Table 3). Proteins encoded by these genes are essential for splicing in all cell types, yet the pathologic effects of mutations in all 3 genes is seen only in rod photoreceptors. Incomplete penetrance is one of the unique features associated with mutations in PRPF31. Asymptomatic carriers can have affected parents and children, which can significantly complicate determining the mode of inheritance, thereby hindering the genetic counseling of the family. Previously, it has been reported that symptomatic individuals experience night blindness and loss of visual field in their teens and are typically registered as blind when they reach their 30s. Detailed haplotype analysis in PRPF31-linked families indicated that asymptomatic patients inherit a different wild-type allele from the one inherited by their symptomatic siblings, suggesting the existence of differentially expressed wild-type alleles that can potentially determine the penetrance of the disease symptoms. The high expression level of the wild-type allele may compensate for the nonfunctional mutant allele, whereas the low-expressing wild-type allele is inadequate to reach the required photoreceptor-specific PRPF31 activity threshold [15, 16].

### Peripherin 2

The peripherin 2 gene (PRPH2), formerly known as the retinal degeneration slow gene (RDS), consists of 3 exons and encodes a 39-kDa integral membrane glycoprotein with 346 amino acids. The protein includes 4 transmembrane domains (M1-M4) and a large intradiscal domain (known as the D2 loop) and is located at the outer segment discs of the rod and cone photoreceptors. It forms a homo-oligomeric structure with itself and a mixture of homotetrameric and heterotetrameric complexes with another membrane protein (ROM1) [17]. This structure is important in disc morphogenesis and stabilization. Mutations in PRPH2 that cause RP were first described in 1991 and account for 5-9.5% of adRP cases. Interestingly, cases of digenic RP have been observed following the simultaneous presence of a mutation in the PRPH2 (RDS) gene and a mutation in the ROM1 gene [18]. In all cases reported, the same PRPH2 (RDS) mutation (L185P) was found, although three different ROM1 mutations were identified in these families. Studies carried out in Prph2Rd2/Rd2 mice have shown that the genetic defect can be corrected both morphologically and functionally by in vivo gene transfer. The ERGs of Prph2Rd2/Rd2 mice have greatly diminished a-wave and b-
wave amplitudes, which decline to virtually undetectable concentrations by two months. Subretinal injection of recombinant adeno-associated virus (AAV) encoding a Prph2 transgene resulted in stable generation of outer segment structures and formation of new stacks of discs containing both peripherin-2 and rhodopsin, which in many cases were morphologically similar to normal outer segments. Moreover, the re-establishment of the structural integrity of the photoreceptor layer also resulted in electrophysiological correction [19].

Retinitis Pigmentosa 1

The Retinitis Pigmentosa 1 (RP1) locus was originally mapped by linkage testing in a large adRP family in southeastern Kentucky and the RP1 gene subsequently identified by positional cloning. Mutations in RP1 cause both dominant and recessive forms of RP. Mutations in the RP1 gene account for approximately 5-10% of all adRP (4% in the United States) with the Arg677X mutation accounting for ½ of the total [from http://www.sph.uth.tmc.edu/retnet/]. The RP1 gene encodes a 240-kD retinal photoreceptor-specific protein. RP1 is expressed prominently, if not only, in the photoreceptor cells of the retina and is involved in the correct orientation and higher order stacking of outer segment discs. RP1 is a microtubule-associated protein forming part of the photoreceptor axoneme and thus plays an important role in photoreceptor function [20, 21]. Clinical characterization of patients with RP1 disease shows notable differences in visual field diameters and ERG amplitudes in patients of the same age who share the same primary mutations. In general, variation in the phenotypes of genetic disorders can be attributed to allelic heterogeneity, environmental factors, and genetic modifiers. For RP1 disease, genetic modifiers are thought to be especially important because variation in the severity of disease is observed in patients with the same primary mutation and because environmental exposures are likely to be relatively similar within families.

Diagnosis of adRP

As for the molecular diagnosis of adRP, an array has recently been developed and shown to enable the analysis of 385 mutations in 16 different genes involved in adRP: CA4, FSCN2, IMPDH1, NRL, PRPF3, PRPF31, PRPF8, RDS, RHO, ROM1, RP1, RP9, CRX, TOPORS, and PNR (www.asperbio.com).

3.2. Autosomal Recessive RP

Over 30 genes and loci (Table 4) have been implicated in autosomal recessive RP (Fig. (2)), even if most of them are rare, causing 1% or fewer cases. However, for some of them (RPE65, PDE6A, PDE6B and RP25) percentages can be higher, up to 2-5% of cases, and will therefore be more thoroughly described.

Retinal Pigment Epithelium 65

Retinal pigment epithelium 65 (RPE65) is an isomerase hydrolyase expressed in retinal pigment epithelium and is critical for the regeneration of the visual pigment necessary for both rod and cone-mediated vision. More than 60 different mutations have been found in the RPE65 gene, accounting for approximately 2% of recessive RP cases and 16% of LCA patients. Several animal models, including the naturally occurring canine (Briard dog) and murine (Rpe65<sup>rd12</sup>) models and the genetically engineered Rpe65<sup>-/-</sup>-knockout mouse, have been widely used for pathological, biochemical, genetic, structural, functional and therapeutic studies (reviewed in [22]). Because of all these relevant models, for RPE65 mutations the mechanism leading to the disease is fairly well understood. The vitamin A derivative 11-cis-retinal is the chromophore of rod and cone visual pigments. As previously described, absorption of light leads to an 11-cis to all-trans isomerization followed by dissociation of all-trans-retinol from the protein moiety (opsin) of the visual pigment holo-complex. Importantly, the crucial all-trans to 11-cis-retinoid isomerization reaction step takes place in the RPE and is catalyzed by RPE65. Rpe65-deficient mice, in fact, lack 11-cis-retinal and consequently no rhodopsin is detectable in their eyes. Instead, these animals show an over-accumulation of retinyl esters, retinoid intermediates of the visual cycle, in the RPE [23].

Results in pre-clinical studies have recently led to three encouraging gene therapy clinical trials in which patients affected by LCA were sub-retinal injected with recombinant adeno-associated viral vectors (rAAV) containing the human RPE65 cDNA [24-26]. Although the purpose of these initial studies was merely to test the safety of the gene transfer agent, all 3 groups did report modest (though significant) improvements in visual acuity. As a result of the groundbreaking positive reports, these three trials (NCT00516477, NCT00643747, NCT00481546, www.clinicaltrials.gov) are ongoing and expanding their patient population to examine treatment safety and efficacy further.

PDE6A, PDE6B, PDE6G

Among the autosomal recessive RP genes so far identified, many encode proteins important in the rod photoreceptor visual transduction cascade. Central among these is the heterotetrameric phosphodiesterase (PDE) 6 complex, consisting of α, β and two γ subunits. The PDE6 complex regulates the intracellular cGMP levels by hydrolyzing cGMP in response to light activation of G protein coupled receptors in cones and rods, thus making it an essential component of the visual phototransduction cascade [27]. In RP, mechanisms that initiate rod photoreceptor death are unclear; however, low levels of PDE6 activity are thought to lead to rod-cone degeneration. One hypothesis is that in PDE6 mutants an influx of calcium (Ca<sup>2+</sup>) causes rod apoptosis, due to lack of PDE activation. Pharmaceutical interventions to block excessive Ca<sup>2+</sup> influx into rods have been attempted with variable success in mouse models (Pde6<sub>6b<sup>al</sup></sub>/Pde6<sub>6b<sup>al</sup></sub> mice) of the disease and Irish Setter dogs. Each subunit of the PDE6 complex is essential for photoreceptor function and maintenance, and, in fact, mutations within PDE6A (coding the phosphodiesterase 6A) and PDE6B (coding the phosphodiesterase 6B) genes are the second most common identifiable cause of arRP (after mutations in the USH2A gene). About 36,000 cases of simplex and familial RP worldwide are due to defects in PDE6 complex, estimated to account for approximately 8% of all diagnosed arRP. In addition, mutations in the β-subunit
| Gene      | Protein                                      | % of all cases | Function                  | Other diseases/phenotypes                  |
|-----------|----------------------------------------------|----------------|---------------------------|--------------------------------------------|
| RP22      | Unknown                                      |                | Unknown                   | None                                       |
| RP29      | Unknown                                      |                | Unknown                   | None                                       |
| RP32      | Unknown                                      |                | Unknown                   | None                                       |
| ABCA4     | ATP-binding cassette, subfamily A (ABC1), member 4 | 2.9            | Retinal metabolism        | Recessive MD, recessive CORD               |
| BEST1     | Bestrophin-1                                 |                | Anion channel             | Dominant RP                                |
| C2ORF71   | Chromosome 2 open reading frame 71           |                | Unknown                   | Dominant RP                                |
| CERKL     | Ceramide kinase-like protein                 |                | Tissue development and maintenance | None                                       |
| CNGA1     | Cyclic nucleotide gated channel alpha1       | 2.3            | Phototransduction         | None                                       |
| CNGB1     | Cyclic nucleotide gated channel beta1        |                | Phototransduction         | None                                       |
| CRB1      | Crumbs homolog 1                             | 6.5            | Tissue development and maintenance | Recessive LCA                             |
| EYS (RP25)| Eyes shut homolog                           |                | Protein of the extracellular matrix | -                                           |
| FAM161A   | Family with sequence similarity 161 member A |                | Unknown, localized in the photoreceptors | -                                           |
| IDH3B     | NAD(+)–specific isocitrate dehydrogenase 3 beta |                | Involved in Krebs cycle   | -                                           |
| IMPG2     | Interphotoreceptor matrix proteoglycan 2     |                | Component of the retinal intercellular matrix | -                                           |
| LRAT      | Lecithin retinol acyltransferase             |                | Retinal metabolism        | Recessive LCA                              |
| MERTK     | C-mer proto-oncogene tyrosine kinase         |                | Transmembrane protein     | None                                       |
| NR2E3     | Nuclear receptor subfamily 2, group E, member 3 |                | Transcription factor      | Dominant RP; Recessive enhanced S-cone syndrome |
| NRL       | Neural retina leucine zipper protein         |                | Tissue development and maintenance | Dominant RP                                |
| PDE6A     | Phosphodiesterase 6A, cGMP-specific, rod alpha | 4.0            | Phototransduction         | None                                       |
| PDE6B     | Phosphodiesterase 6B, cGMP-specific, rod beta | 4.0            | Phototransduction         | Dominant CSNB                              |
| PDE6G     | Phosphodiesterase 6G, cGMP-specific, rod gamma |                | Phototransduction         |                                            |
| PRCD      | Progressive rod-cone degeneration            |                | Unknown function          | -                                          |
| PROM1     | Prominin 1                                   |                | Cellular structure        | Recessive RP with macular degeneration      |
| RBP3      | Retinol binding protein 3                    |                | Retinal metabolism        | -                                          |
| RGR       | Retinal G protein–coupled receptor           |                | Retinal metabolism        | Dominant choroidal sclerosis               |
| RHO       | Rhodopsin                                    |                | Phototransduction         | Dominant RP                                |
| RLBP1     | Retinaldehyde-binding protein 1              |                | Retinal metabolism        | Recessive Bothnia dystrophy                |
| RP1       | RP-1 protein                                 |                | Tissue development and maintenance | Dominant RP                                |
of \textit{PDE6B} can lead to either progressive retinal disease, such as RP, or stationary disease, such as congenital stationary night blindness (CSNB). Heterozygous carriers of \textit{PDE6} mutations are at a risk of losing vision when excessively inhibiting PDE6 with drugs such as sildenafil, tadalafil, or vardenafil [28]. More recently, a mutation (c187+1G>T) in the \textit{PDE6G} gene encoding the gamma subunit of the rod cGMP phosphodiesterase was reported, thus confirming the involvement of PDE6G in autosomal-recessive early-onset RP [29].

\textbf{RP25}

Other mutations, while rare elsewhere, can be a common cause of arRP in specific populations, such as the RP25 locus which was identified as the genetic cause of 10-20\% of arRP cases in Spain [30].

\textbf{Diagnosis of arRP}

Tests available to screen mutations involved in arRP are so far well developed and able to detect up to 594 different mutations from several arRP-related genes including \textit{CERKL, CNGA1, CNGB1, MERTK, PDE6A, PDE6B, PNR, RDH12, RGR, RLBP1, SAG, TULP1, CRB, RPE65, USH2A, USH3A, LRAT, PROML1 and PBP3}. In addition, many diagnostic laboratories offer the possibility to have the entire coding region of the RPE65, PDE6 and USH2A genes sequenced.

\subsection*{3.3. X-Linked RP}

Around 10\%-15\% of RP patients have X-Linked RP (XLRP; Fig. 3) and are characterized by a severe phenotype in the early stages of disease development. A milder phenotype can sometimes occur in female carriers, probably due to non-random or skewed inactivation of one X chromosome. In some patients, abnormal sperm development, impaired hearing and defects in the respiratory tract were observed, thus underlying the ciliary background of the disease (reviewed in [31]).

Six gene loci responsible for XLRP have been mapped on the X-chromosome (RP6, RP23, RP24, RP34, RP2 and RPGR – Table 5), but only two of these have been identified so far: the retinitis pigmentosa GTPase regulator (\textit{RPGR}) or \textit{RP3}) and the retinitis pigmentosa 2 protein (\textit{RP2}).

The \textit{RPGR}/\textit{RP3} gene product localizes in the outer segment of rod photoreceptors and is essential for their viability. Around 70\% of XLRP patients have mutations in the \textit{RPGR}/\textit{RP3} gene. However, only 20\% of the RP3

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|c|c|}
\hline
Gene & Protein & \% of all cases & Function & Other diseases/phenotypes \\
\hline
RP2 & Retinitis pigmentosa 2 protein & 15.1 & Human cofactor C is involved in beta-tubulin folding & None \\
\hline
RP6 & Unknown & & Unknown & None \\
\hline
RP23 & Unknown & & Unknown & None \\
\hline
RP24 & Unknown & & Unknown & None \\
\hline
RP34 & Unknown & & Tissue development and maintenance & None \\
\hline
RPGR & Retinitis pigmentosa GTPase regulator & 74.2 & Intraflagellar transport & X-linked COD, X-linked CSNB \\
\hline
\end{tabular}
\caption{Genes, Proteins and their Functions in X-Linked RP (Adapted from [6, 9] and http://www.sph.uth.tmc.edu/retnet/)}
\end{table}
mutations occur within the exons coding for RPGR, while the ORF15 region turned out to be a mutational hotspot, with a mutation rate of 30-60% of all XLRP cases [32].

The predicted RP2 gene product shows homology with human cofactor C, a protein involved in the ultimate step of beta-tubulin folding. Progressive retinal degeneration may therefore be due to the accumulation of incorrectly-folded photoreceptor or neuron-specific tubulin isoforms followed by progressive cell death. The gene responsible for RP2 was first cloned in 1998 and approximately 10-15% of XLRP patients have mutations in this gene. In contrast to RPGR, missense mutations and mutations leading to a truncated protein are distributed throughout the RP2 sequence (reviewed in [31]).

Differently from other forms, in X-linked RP, the two genes RPGR and RP2 alone account for more than 80% of the clinical cases and are therefore better target candidates for small-molecule drug or gene therapy approaches. As for the genetic analysis, a screening test able to evaluate up to 184 mutations in RP2 and RPGR (excluding ORF15) genes is currently available (www.asperbio.com).

4. SYNDROMIC RETINITIS PIGMENTOSA

In the majority of cases, RP is an isolated disorder (simple or non-syndromic), but there are also syndromic forms. In addition, infrequently, RP can also be found associated with other systemic conditions such as abetalipoproteinemia and Refsum disease. For the purpose of this review paper, we will only describe the more frequent of these syndromes, namely Usher syndrome and Bardet-Biedl syndrome.

4.1. Usher Syndrome

Usher syndrome (USH) is an autosomal recessive disease characterized by the association of hearing loss, retinitis pigmentosa, and, in some cases, vestibular dysfunction. The syndrome is the most frequent cause of deaf-blindness, accounting for more than 50% of individuals who are both deaf and blind and affects between 1:12,000 – 1:30,000 people in different populations. The Usher cases may represent between 10-30% of all autosomal recessive RP cases (reviewed in [31]).

Clinically, USH is divided into three types. Usher type I (USH1) is the most severe form and is characterized by severe to profound congenital deafness, vestibular areflexia, and pre-puberal onset of progressive RP. Type II (USH2) displays moderate to severe hearing loss, absence of vestibular dysfunction, and later onset of retinal degeneration. Type III (USH3) shows progressive post-lingual hearing loss, variable onset of RP, and variable vestibular response.

To date, five USH1 genes have been identified: MYO7A (USH1B), CDH23 (USH1D), PCDH15 (USH1F), USH1C(USH1C), and USH1G(USH1G). Three genes are involved in USH2, namely, USH2A (USH2A), GPR98 (USH2C), and DFNB31 (USH2D). USH3 is rare except in certain populations (Finns and Ashkenazi Jews), and the gene responsible for this type is USH3A (Table 6).

Currently, there is no treatment available for USH. As for the diagnosis, an updated version of the Usher micro-array has recently been implemented by Asper Biotech (Tartu, Estonia) allowing to screen 612 mutations in the genes CDH23, MYO7A, PCDH15, Harmonin, SANS, USH2A, VLGR1, USH3A, and Whirlin.

4.2. Bardet-Biedl Syndrome

Bardet-Biedl syndrome (BBS) is characterized by rod-cone dystrophy (>90%), truncal obesity (72%), postaxial polydactyly, cognitive impairment, male hypogonadotrophic hypogonadism, complex female genitourinary malformations, and renal abnormalities. Renal disease is a major cause of morbidity and mortality. Birth weight is usually normal, but significant weight gain begins within the first year and becomes a lifelong issue for most individuals.

The visual prognosis for children with BBS is poor. Night blindness is usually evident by age seven to eight years and the mean age of legal blindness is 15.5 years. Atypical pigmentary retinal dystrophy with early macular involvement is the characteristic fundus abnormality in BBS [34, 35]. Visual acuity (central retinal function mediated by cones), dark adaptation, and peripheral visual fields (peripheral retina function mediated by rods) are all affected.

BBS is typically inherited in an autosomal recessive manner and affects 1 individual in 120,000 Caucasians. A higher incidence has been reported in isolated populations of Newfoundland (1 in 13000) [36] and among the Bedouins (ranging between 1:13500 and 1:6900 among the Bedouin population in the Jahra district) [37]. Fourteen genes are known to be associated with BBS: BBS1 (mutated in 40% of BSS families), BBS2 (mutated in 20% of BSS families), ARL6/BBS3, BBS4 (mutated in 3-6% of BSS families), BBS5 (mutated in 2% of BSS families), MKKS/BBS6, BBS7, TTC8/BBS8, B1/BBS9, BBS10, TRIM32/BBS11, BBS12, MKS1/BBS13, and CEP290/BBS14 (from http://www.sph.uth.tmc.edu/retinet/). Molecular genetic testing is currently available on a clinical basis for all 14 known BBS-related genes. However, approximately 20% of persons with BBS do not have identifiable mutations in any of the 14 genes and therefore, it is possible that more BBS-related genes are yet to be identified.

5. FUTURE DIRECTIONS

A reasonable hope is that in the near future, molecular testing of newly diagnosed patients with RP will be a routine part of clinical practice and will uncover the underlying disease-causing mutations in at least 95% of cases. However, for this hope to come true, the following conditions will need to be met:

a. Most of the genes causing RP must be identified. In spite of the large number of genes identified to date, the fraction of patients in which a mutation can be found by screening the known genes is often low;

b. It should be possible to detect nearly all of the disease-causing mutations within these genes;

c. Molecular testing should be inexpensive, reliable, fast and widely available;
Clinicians must be able to understand, interpret and explain the molecular information.

Several strategies do exist and novel technologies are emerging that increase the chance to identify the causative mutation in patients. Array-based diagnostic tests have nowadays been established for several retinal diseases, including RP; but allow to detect only known mutations. Next generation sequencing techniques, that is, novel gene selection and targeting methods followed by massively-parallel, ultra-high-throughput sequencing, offer a rapid, efficient way to find disease-causing mutations in affected individuals and to discover new disease genes. These techniques have recently been applied to finding genes and mutations causing adRP in individuals/families in which conventional testing failed to detect mutations in known genes [38, 39].

However, an important challenge for all these genetic tests is the interpretation of the results obtained. Many of the DNA sequence variations lead to amino acid substitutions and it is difficult to predict the pathogenic effects for many of them. Functional assays would therefore be needed to characterize these sequence alterations, but, due to the extensive individuality of pathogenic and non-pathogenic sequences, this approach would be difficult to realize in a routine diagnostic setting.

What we really need today are comprehensive databases integrating genetic and clinical data in order to perform detailed genotype-phenotype comparisons. This would allow to reveal important information not only to diagnose RP in a patient or family for genetic counseling, but it may also have a predictive value with respect to the likelihood of disease development and choices of therapy (nutrition supplements, drugs, gene replacement strategies, stem cell technologies, etc.) [40].

**ACKNOWLEDGEMENTS**

This work was supported partly through a donation of the “RP Triveneto ONLUS - Associazione per la Retinite Pigmentosa e l’Ipovisione del Triveneto” and a grant from the Regione Veneto (Ricerca Sanitaria Finalizzata 2009).

**REFERENCES**

[1] Hartong, D.T.; Berson, E.L.; Dryja, T.P. Retinitis pigmentosa. *Lancet*, 2006, 368(9549), 1795-1809.

[2] Marigo, V. Programmed cell death in retinal degeneration: targeting apoptosis in photoreceptors as potential therapy for retinal degeneration. *Cell Cycle*, 2007, 6(6), 652-655.

[3] Hamel C. Retinitis pigmentosa. *Orphanet J. Rare Dis.*, 2006, 1, 40.

[4] Grover, S.; Fishman, G.A.; Anderson, R.J.; Tzotzil, M.S.; Heckenlively, J.R.; Weleber, R.G.; Edwards, A.O.; Brown, J., Jr. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. *Ophthalmology*, 1999, 106(9), 1780-1785.

[5] Bhattacharya, S.S.; Wright, A.F.; Clayton, J.F.; Price, W.H.; Phillips, C.I.; McKeown, C.M.; Jay, M.; Bird, A.C.; Pearson, P.J.; Southern, E.M. Close genetic linkage between X-linked retinitis pigmentosa and a restriction fragment length polymorphism identified by recombinant DNA probe L1.28. *Nature*, 1984, 309(5965), 253-255.

[6] Berger, W.; Kloekendener-Gruissem, B.; Neidhardt, J. The molecular basis of human retinal and vitreoretinal diseases. *Prog Retin. Eye Res.*, 2010, 29(5), 335-375.

[7] Daiger, S.P.; Bowne, S.J.; Sullivan, L.S. Perspective on genes and mutations causing retinitis pigmentosa. *Arch. Ophthalmol.*, 2007, 125, 151-158.

[8] Redmond, T.M.; Yu, S.; Lee, E.; Bok, D.; Hamasaki, D.; Chen, N.; Goletz, P.; Ma, I.X.; Crouch, R.K.; Pfefler, K. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. *Nat. Genet.*, 1998, 20(4), 344-351.

[9] Moiseyev, G.; Chen, Y.; Takahashi, Y.; Wu, B.X.; Ma, J.X. RPE65 is the isomerohydrolase in the retinoid visual cycle. *Proc. Natl. Acad. Sci. U S A*, 2005, 102(35), 12413-12418.

[10] Murray, A.R.; Fliesler, S.J.; Al-Ubaidi, M.R. Rhodopsin: the functional significance of Asn-linked glycosylation and other post-translational modifications. *Ophthalmic Genet.*, 2009, 30(3), 109-120.
Retinitis Pigmentosa

Current Genomics, 2011, Vol. 12, No. 4 249

Fitzke, F.W.; Carter, B.J.; Rubin, G.S.; Moore, A.T.; Ali, R.R.; Tyler, N.; Petersen-Jones, S.; Bhattacharya, S.S.; Thrasher, A.J.; Bainbridge, J.W.; Smith, A.J.; Barker, S.S.; Robbie, S.; Henderson, M.; Reilly, M.; Titus, E.; Fauser, S.; Reichel, M.B.; Kinnon, C.; Hunt, S.; Dell'Osso, L.; Hertle, R.; Ma, J.X.; Redmond, T.M.; Zhu, X.; Hauck, B.; Zelenala, O.; Shindler, K.S.; Maguire, M.G.; Wright, J.F.; Volpe, N.J.; McDonnell, J.W.; Auricchio, A.; High, K.A.; Bennett, J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med., 2008, 358(21), 2240-2248.

Tsang, S.H.; Burns, M.E.; Calvert, P.D.; Gouras, P.; Baylor, D.A.; Goff, S.P.; Arshavsky, V.Y. Role for the target enzyme in deactivation of photoreceptor G protein in vivo. Science, 1998, 282(5386), 117-121.

Tsang, S.H.; Tsui, I.; Chou, C.L.; Zernant, J.; Haamer, E.; Iranmanesh, R.; Tosi, J.; Allikmets, R. A novel mutation and phenotypes in phosphodiesterase 6 deficiency. Am. J. Ophthalmol., 2008, 146(5), 780-788.

Divir, L.; Soug, G.; Abu-Ras, R.; Miller, B.; Shalev, S.A.; Ben-Yosef, T. Autosomal-recessive early-onset retinitis pigmentosa caused by a mutation in PDE6G, the gene encoding the gamma subunit of rod cGMP phosphodiesterase. Am. J. Hum. Genet., 2010, 87(2), 258-264.

Barraclough, N.; Abd, El-Aziz, M.M.; Borrego, S.; El-Ashry, M.F.; O'Driscoll, C.; Bhattacharya, S.S.; Antinolli, G. Linkage validation of RP25 using the 10K GeneChip array and further refinement of the locus by new linked families. Ann. Hum. Genet., 2008, 72 (Pt 4), 454-462.

Veltel, S.; Wittinghofer, A. RPGR and RP2: targets for the treatment of X-linked retinitis pigmentos? Expert. Opin. Ther. Targets, 2009, 13(10), 1239-1251.

Vervoort, R.; Lennon, A.; Bird, A.C.; Tulloch, B.; Axton, R.; Miano, M.G.; Meindl, A.; Meitinger, T.; Ciccocioppo, A.; Wright, A.F. Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa. Nat. Genet., 2000, 25(4), 462-466.

Millan, J.M.; Aller, E.; Gao, J.T.; Blaco-Kelly, F.; Gimenez-Pardo, A.; Ayuso, C. An update on the genetics of Usher Syndrome. J. Ophthalmol., 2011, DOI: 10.1155/2011/417217.

Héon, E.; Wesell, C.; Carmi, R.; Elbedour, K.; Panton, C.; Macken, L.; Stone, E.M.; Sheffield, V.C. Ocular phenotypes of three genetic variants of Bardet-Biedl syndrome. Am. J. Med. Genet. A., 2005, 132A(3), 283-287.

Azari, A.A.; Aleman, T.S.; Cideciyan, A.V.; Schwartz, S.B.; Windsor, E.A.; Sumaroka, A.; Cheung, A.Y.; Steinberg, J.D.; King, J.; Beales, P.L.; Katsanis, N.; Bassett, A.S.; Davidson, W.S.; Farrey, P.S. Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort study. Am. J. Med. Genet. A., 2005, 132(4), 352-360.

Teebi, A.S. Autosomal recessive disorders among Arabs: an overview from Kuwait. J. Med. Genet., 1994, 31, 224-233.

Daiger, S.P.; Sullivan, L.S.; Bowne, S.J.; Bird, D.G.; Heckenlively, J.R.; Pierce, E.A.; Weinstock, G.M. Targeted high-throughput DNA sequencing for gene discovery in retinitis pigmentosa. Adv. Exp. Med. Biol., 2010, 664, 325-331.

Bowne, S.J.; Sullivan, L.S.; Koboldt, D.C.; Ding, L.; Fulton, R.; Abbott, R.M.; Sodergren, E.J.; Bird, D.G.; Wheaton, D.H.; Heckenlively, J.R.; Liu, Q.; Pierce, E.A.; Weinstock, G.M.; Daiger, S.P. Identification of Disease-Causing Mutations in Autosomal Dominant Retinitis Pigmentosa (adRP) Using Next-Generation DNA Sequencing. Invest. Ophthalmol. Vis. Sci., 2011, 52(1), 494-503.

Musarella, M.A.; Macdonald, I.M. Current concepts in the treatment of retinitis pigmentosa. J. Ophthalmol., 2011, 2011, 753547.